Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). One-time retention awards approved for CEO, CFO, and CMO, signaling efforts to preserve executive continuity through June 30, 2027.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- One-time retention awards approved for CEO, CFO, and CMO, signaling efforts to preserve executive continuity through June 30, 2027
- Cash awards total $2.91 million, payable around July 15, 2026 and repayable upon qualifying early departures
- RSU awards total 1,092,600 shares, vesting June 30, 2027 or upon qualifying termination
- CEO Ameet Mallik received $1,795,500 cash and 675,000 RSUs, the largest package by a wide margin
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.